Legend Biotech shareholders back directors, auditor, and share plan increase at 2026 AGM
At its September 24, 2026 annual meeting, Legend Biotech investors re-elected four directors and approved adding 19.1 million shares to its restricted share plan.
Legend Biotech Corporation held its 2026 Annual General Meeting of Shareholders on September 24, 2026, according to a Form 6-K filed with the SEC. Roughly 330,199,682 ordinary shares, including those represented by ADSs, took part in person or by proxy, equal to about 84.9% of the 388,976,826 ordinary shares outstanding as of the August 17, 2026 record date.1
Shareholders received the company's audited consolidated financial statements for fiscal year 2025 and confirmed Ernst & Young LLP as its independent auditor for fiscal year 2026.1
Four Class III director nominees were re-elected to three-year terms: Robin Meng, Corazon D. Sanders, Li Mao, and Peter Salovey. Meng's re-election drew 273,381,862 votes in favor, representing 70.282%, against 56,768,390 votes opposed, or 14.594%.1 The other three nominees each received more than 83% support.
Shareholders also approved changes to the company's 2020 Restricted Shares Plan, described in the filing as an amendment and restatement of the plan to add 19,100,000 ordinary shares to the pool reserved for issuance.1 That measure passed with 279,130,008 votes in favor, or 71.760%, 20,732,988 votes against, or 5.330%, and 30,336,686 abstentions, or 7.799%.1
The filing was signed by Chief Executive Officer Ingrid Zhang.
Fact check notes
- Sentence removed
A final resolution authorizing directors and officers to carry out the meeting's decisions also passed, with 328,624,268 votes in favor.
a figure with no citation
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.